Sonics × Future

Sonics Brings New Future to Cancer Patients

A new future for cancer patients using sonics

SONIRE Therapeutics Inc.

シニアドクター
 
Happy Patient

High Intensity Focused Ultrasound (HIFU) treatment

×

Pancreatic cancer

Each year in Japan, 40,000 people are diagnosed with pancreatic cancer and 36,000 people die from it. The 5-year survival rate is low at 9.9%, and because early detection is difficult, it is known as one of the intractable cancers.

High Intensity Focused Ultrasound (HIFU) treatment involves the application of a focused ultrasound on cancer tissue and treating it using heating effects without cutting it. Furthermore, there is no exposure to radiation, and because it is a minimally invasive treatment method that does not use needles or anesthesia, it is gaining attention as the next generation standard of care for cancer.

 
 
デジタルタブレットを使用してドクター

Our Vision

Solving challenges of the existing treatments

as the next generation standard of care for cancer

Benefits of the High Intensity Focused Ultrasound treatment

  • Treating cancer without cutting it and maintaining the body’s organs and functions

  • Enables operability and improves prognosis

  • Repeated treatments are possible because there is no radiation exposure or secondary cancer

  • Reduces anticancer drug dosages and side effects

All existing standard cancer treatments still have challenges

Surgery

  • Wound healing and general recovery take time

  • Possibility of organs and body losing function

  • Not applicable to cancers in inoperable locations

Radiation

  • Limits on beams due to risks involving exposure to radiation

  • Radiation damage to the irradiated area

  • Systemic symptoms such as dizziness may occur​

Drugs

  • Drug therapy reduces immune functions

  • Side effects affect healthy cells

  • Limited efficacy if used as the sole treatment

 

Management Team

Tohru Satoh, MBA
President & CEO

Engaged in overseas expansion of Opdivo at Ono Pharma and in license activity as Senior Director of Business Planning Div. at Oncolys Bio Pharma and Board Member of Liquid Biotech USA

Jun Okamoto, PhD
VP & COO

Engaged in practical development of surgical support robots and smart operation rooms at Tokyo Women’s Medical University.

Hiroko Kimura, PhD
Board Member

Fast Track Initiative, Inc.

Shin Yoshizawa, PhD
Technical Founder

Tohoku Univ., Dept. of Comm. Eng., Professor

Specialty :  Fluid Eng., Bubble, HIFU, Sonodynamic therapy, US imaging

Atsushi Sofuni, M.D./PhD

Tokyo Medical Univ., Dept. of Gastroenterology

and Hepatology, Associate Professor

Specialty : Biliary Pancreatic, HIFU treatment for Pancreatic cancer.

Shinichiro Umemura, PhD
Technical Advisor

Tohoku Univ., Biomedical Eng., Prof. Emeritus, Researcher, IEEE Fellow

Specialty :  Therapeutic ultrasound, Sonochemistry, US imaging

Company overview

logo2.png